138 related articles for article (PubMed ID: 21646477)
1. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
Yang H; Robinson SN; Nieto Y; Jones RJ; Gocke CD; Lu J; Giralt SA; Jones RB; Decker WK; Xing D; Steiner D; Champlin RE; McMannis JD; Ng J; Thomas MW; Shah N; Andersson BS; Parmar S; Shpall EJ
Cancer Res; 2011 Jul; 71(14):5040-9. PubMed ID: 21646477
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
3. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
[TBL] [Abstract][Full Text] [Related]
5. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.
Bourhis JH; Bouko Y; Koscielny S; Bakkus M; Greinix H; Derigs G; Salles G; Feremans W; Apperley J; Samson D; Björkstrand B; Niederwieser D; Gahrton G; Pico JL; Goldschmidt H;
Haematologica; 2007 Aug; 92(8):1083-90. PubMed ID: 17640853
[TBL] [Abstract][Full Text] [Related]
6. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
Widmer L; Pichert G; Jost LM; Stahel RA
Blood; 1996 Oct; 88(8):3166-75. PubMed ID: 8874217
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of CD34+ cell-selected peripheral blood stem cells.
Kawabata Y; Hirokawa M; Komatsuda A; Sawada K
Ther Apher Dial; 2003 Jun; 7(3):298-304. PubMed ID: 12924604
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells.
Vogel W; Behringer D; Scheding S; Kanz L; Brugger W
Blood; 1996 Oct; 88(7):2707-13. PubMed ID: 8839866
[TBL] [Abstract][Full Text] [Related]
9. A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood.
Louis SA; Zapf R; Clarke E; Thomas TE; Sutherland HJ
Cytotherapy; 2001; 3(6):489-504. PubMed ID: 11953033
[TBL] [Abstract][Full Text] [Related]
10. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
11. Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation.
Rambaldi A; Borleri G; Dotti G; Bellavita P; Amaru R; Biondi A; Barbui T
Blood; 1998 Mar; 91(6):2189-96. PubMed ID: 9490708
[TBL] [Abstract][Full Text] [Related]
12. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
Siveen KS; Mustafa N; Li F; Kannaiyan R; Ahn KS; Kumar AP; Chng WJ; Sethi G
Oncotarget; 2014 Feb; 5(3):634-48. PubMed ID: 24504138
[TBL] [Abstract][Full Text] [Related]
13. Positive selection of autologous peripheral blood stem cells.
Lopez M; Beaujean F
Baillieres Best Pract Res Clin Haematol; 1999; 12(1-2):71-86. PubMed ID: 11000984
[TBL] [Abstract][Full Text] [Related]
14. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
Vescio R; Schiller G; Stewart AK; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; DiPersio J; Anderson K; Berenson J
Blood; 1999 Mar; 93(6):1858-68. PubMed ID: 10068658
[TBL] [Abstract][Full Text] [Related]
16. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
17. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
Horvath N; Hahn U; Joshua D; Dyson P; Gibson J; Stevens J; Rawling T; Barrow L; Brown R; Stephens S; Gower G; Norman J; Mills B; To LB
Intern Med J; 2004 Apr; 34(4):167-75. PubMed ID: 15086696
[TBL] [Abstract][Full Text] [Related]
19. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
[TBL] [Abstract][Full Text] [Related]
20. A method for clinical purging of myeloma bone marrow using peanut agglutinin as an anti-plasma cell agent, in combination with CD19 monoclonal antibody.
Rhodes EG; Baker PK; Duguid JK; Davies JM; Cawley JC
Bone Marrow Transplant; 1992 Dec; 10(6):485-9. PubMed ID: 1490198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
